LUTEOSYL(d)-Cloprostenol mg/ml Solution for injection for cattle and pigs

Similar documents
SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Health Products Regulatory Authority

LABELLING AND PACKAGE LEAFLET

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

B. PACKAGE LEAFLET 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

[Version 8, 10/2012] SUMMARY OF PRODUCT CHARACTERISTICS

Vetoquinol/DOLPAC Small dogs/european Renewal June 2011 SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX III LABELLING AND PACKAGE LEAFLET

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

SUMMARY OF PRODUCT CHARACTERISTICS

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese

Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle

SUMMARY OF THE PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER

SUMMARY OF PRODUCT CHARACTERISTICS. Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN

Irish Medicines Board

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS VIRBAGEN OMEGA - EN 1

Irish Medicines Board

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33

B. PACKAGE LEAFLET 1

SUMMARY OF PRODUCT CHARACTERISTICS. Lincomycin (as Lincomycin hydrochloride) Neomycin (as Neomycin sulphate) Excipients Disodium edetate

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate

SUMMARY OF PRODUCT CHARACTERISTICS

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Irish Medicines Board

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT In France, Germany, Hungary, Italy, Poland, Spain and The Netherlands; LUTEOSYL 0.075 mg/ml solution for injection for cattle and pigs. In United Kingdom: PRELLIM 0.075 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: d-cloprostenol (as d-cloprostenol sodium)... 0.075 mg/ml Excipients: Chlorocresol... 1 mg/ml For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless solution, free from particles in suspension. 4. CLINICAL PARTICULARS 4.1. Target species Cattle (cows) and pigs (sows). 4.2. Indications for use, specifying the target species Cattle (cows) Indications for reproduction: synchronization or induction of oestrus. Induction of parturition. Therapeutic indication: ovarian dysfunction (persistent corpus luteum, luteal cyst), interruption of pregnancy including foetal mummification, endometritis/pyometra, delayed uterine involution. Pigs (sows) Indications for reproduction: Induction of parturition. 4.3 Contraindications

See section 4.7 Do not use in case of hypersensitivity to the active substance, or to any of the excipients. Do not use in animal with spastic respiratory or gastro-intestinal diseases. 4.4 Special warnings for each target species None. 4.5 Special precautions for use Special precautions for use in animals To reduce the risk of anaerobic infections care should be taken to avoid injection through contaminated areas of skin. Clean and disinfect injection sites thoroughly before application. Pigs: use only when precise date of insemination is known. Administer on day 113 of gestation, at the earliest. The veterinary medicinal product administered earlier, may impair the viability and weight of piglets. Special precautions to be taken by the person administering the veterinary medicinal product to animals d-cloprostenol, like all F2 prostaglandins, can be absorbed through the skin and can produce bronchospasm and abortion. Women of child-bearing age, asthmatics and persons with bronchial problems or any other type of respiratory problem must avoid any contact or use disposable plastic gloves when administering the veterinary medicinal product. The veterinary medicinal product must be handled carefully to avoid ACCIDENTAL SELF-INJECTION OR SKIN CONTACT. Do not eat, drink or smoke while handling the veterinary medicinal product. In case of accidental self injection seek medical advice and show the label to the physician. Seek medical advice immediately in case of any respiratory difficulty caused by accidental inhalation or inoculation. In case of accidental skin contact, wash with soap and water immediately. 4.6 Adverse reactions (frequency and seriousness) Occurrence of anaerobic infection is likely if anaerobic bacteria penetrate the tissue of the injection site. This applies especially to intramuscular injection and

in particular to cows. Typical local reactions due to anaerobic infection are swelling and crepitus at the injection site. 4.7 Use during pregnancy, lactation or lay Do not use (during the whole or part of the pregnancy) unless it is desirable to induce parturition or therapeutic interruption of pregnancy. 4.8 Interaction with other medicinal products and other forms of interaction Do not use in animals being treated with non-steroidal anti-inflammatories, as the synthesis of endogenous prostaglandins is inhibited. The activity of other oxytocic agents can be increased after the administration of Cloprostenol. 4.9 Amounts to be administered and administration route For intramuscular use only: Cattle(cows): The recommended dose is 0.150 mg d-cloprostenol/animal, equivalent to 2 ml/animal. - Oestrus induction (also in cows with weak or silent heat): After determining the presence of corpus luteum (day 6-18 of the cycle), administer the veterinary medicinal product. Heat is generally observed in 48-60 hours. Inseminate 72-96 hours after this treatment. If heat is not observed, repeat after 11 days. - Parturition induction: Administer the veterinary medicinal product after gestation day 270. Parturition should occur 30-60 hours post-treatment. - Oestrus synchronisation: Administer the veterinary medicinal product twice (11 days apart). Inseminate artificially 72 and 96 hours after the second injection. - Ovarian dysfunction: Once the presence of corpus luteum is determined, administer the veterinary medicinal product and inseminate in the first heat after the treatment. If no heat is observed, carry out a gynaecological examination again and repeat the injection 11 days after the first treatment. Insemination is 72-96 hours post-treatment. - Endometritis or pyometra: Administer 1 dose of the veterinary medicinal product. Repeat the treatment 10-11 days later if necessary. - Gestation interruption: Administer the veterinary medicinal product during the first half of gestation. - Foetal mummification: Administer 1 dose of veterinary medicinal product. The foetus will be expelled after 3 or 4 days. - Retarded uterine involution: Administer 1 dose of the veterinary medicinal product and, if indicated, repeat the treatment once or twice at 24 hour interval. Pigs(sows): The recommended dose is 0.075 mg d-cloprostenol/animal, equivalent to 1 ml/animal.

- Parturition induction: Administer the veterinary medicinal product after day 112 of gestation. Repeat after 6 hours. Alternatively, 20 hours after the initial dose of d-cloprostenol, a myometrial stimulant (oxytocin or carazolol) may be administered. Following the protocol of double administration, in about 70% of cases, parturition occurs 20-30 hours after the first treatment. 4.10 Overdose (symptoms, emergency procedures, antidotes) if necessary In safety studies, at 10 times the therapeutic dose, no adverse reactions are reported. As no specific antidote has been identified, in the case of overdose, symptomatic therapy is advisable. 4.11 Withdrawal period(s) Cows: Meat and offal: 1 day. Milk: 0 hours. Sows: Meat and offal: 1 day. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Uterotonics. Prostaglandins. ATCvet code: QG02AD90. 5.1 Pharmacodynamic properties The veterinary medicinal product is based on dextrorotatory cloprostenol (d- Cloprostenol), a synthetic analogue of prostaglandin F2. d-cloprostenol is the biologically active luteolytic component of cloprostenol and results in an approximately 3.5 fold increase in activity. During the luteinizing stage of the oestrus cycle d-cloprostenol induces a rapid regression of the corpus luteum and a decrease in progesterone levels. The increased release of follicle stimulating hormone (FSH) allows a new follicle to mature, followed by oestrus and ovulation. 5.2 Pharmacokinetic particulars Pharmacokinetic studies demonstrate a rapid absorption of d-cloprostenol. The peak blood level is reached a few minutes following intramuscular administration, as well as a rapid diffusion to the ovaries and uterus, the organs in which the maximum concentration is reached 10-20 minutes after administration. Following intramuscular administration of 150 micrograms of d-cloprostenol in the cow, the peak plasma level ( Cmax) of 1.4 micrograms/l is reached after

approximately 90 minutes, while the elimination half life ( t½) is in the order of 1 hour 37 minutes. In sows, a Cmax of approximately 2 micrograms/l is observed between 30 and 80 minutes following administration of 75 micrograms d-cloprostenol, with an elimination half life in the order of 3 hours 10 minutes. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Chlorocresol Ethanol (96%) Citric acid monohydrate Sodium hydroxide Water for injections. 6.2 Incompatibilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 28 days. 6.4 Special precautions for storage Protect from light. Avoid introduction of contamination. 6.5 Nature and composition of immediate packaging Colourless type II glass vial with type I bromobutyl rubber stopper and aluminium cap.one glass vial of 2 ml in a cardboard box. One glass vial of 10 ml in a cardboard box. One glass vial of 20 ml in a cardboard box. Five glass vials of 20 ml in a cardboard box Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Laboratorios SYVA, S.A.U. Avda. Párroco Pablo Díez, 49-57 24010 LEÓN - SPAIN

8. MARKETING AUTHORISATION NUMBER 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 10. DATE OF REVISION OF THE TEXT December 2013 PROHIBITION OF SALE, SUPPLY AND/OR USE For animal treatment only. To be supplied only on veterinary prescription.

LABELLING AND PACKAGE LEAFLET

A. LABELLING

OUTER PACKAGE 1 VIAL OF 2 ml/ 1 VIAL OF 10 ml/ 1 VIAL OF 20 ml/ 5 VIALS OF 20 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT In France, Germany, Hungary, Italy, Poland, Spain and The Netherlands; LUTEOSYL 0.075 mg/ml solution for injection for cattle and pigs. d-cloprostenol In United Kingdom: PRELLIM 0.075 mg/ml solution for injection for cattle and pigs. d-cloprostenol 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES d-cloprostenol (as d-cloprostenol sodium)... 0.075 mg/ml Chlorocresol... 1 mg/ml 3. PHARMACEUTICAL FORM Solution for injection. 4. PACKAGE SIZE 2 ml 10 ml 20 ml 5 x 20 ml. 5. TARGET SPECIES 6. INDICATION(S) 7. METHOD AND ROUTE(S) OF ADMINISTRATION Intramuscular use. Read the package leaflet before use.

8. WITHDRAWAL PERIOD Cows: Meat and offal: 1 day. Milk: 0 hours. Sows: Meat and offal: 1 day. 9. SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use 10. EXPIRY DATE EXP {month/year} Once opened, used by Shelf life after first opening the container: 28 days 11. SPECIAL STORAGE CONDITIONS Protect from light. Avoid introduction of contamination. Keep the vial in the outer carton. 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY Disposal: read package leaflet. 13. THE WORDS FOR ANIMAL TREATMENT ONLY AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APLICABLE. For animal treatment only - to be supplied only on veterinary prescription. 14. THE WORDS KEEP OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER LABORATORIOS SYVA, S.A.U. Avda. Párroco Pablo Díez, 49-57 24010 LEÓN - SPAIN

16. MARKETING AUTHORISATION NUMBER(S) 17. MANUFACTURER'S BATCH NUMBER Batch {number}

LABEL VIAL OF 2ml/ 10 ml/ 20 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT In France, Germany, Hungary, Italy, Poland, Spain and The Netherlands; LUTEOSYL 0.075 mg/ml solution for injection for cattle and pigs. d-cloprostenol In United Kingdom: PRELLIM 0.075 mg/ml solution for injection for cattle and pigs d-cloprostenol 2. QUANTITY OF THE ACTIVE SUBSTANCE 0.075 mg/ml 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 2 ml 10 ml 20 ml 4. ROUTE(S) OF ADMINISTRATION Intramuscular use. 5. WITHDRAWAL PERIOD Cows: Meat and offal: 1 day. Milk: 0 hours. Sows: Meat and offal: 1 day. 6. BATCH NUMBER Batch {number} 7. EXPIRY DATE EXP {month/year} Shelf life after first opening the container: 28 days. Once opened, used by 8. THE WORDS FOR ANIMAL TREATMENT ONLY

For animal treatment only

B. PACKAGE LEAFLET

PACKAGE LEAFLET: 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder and manufacturer responsible for batch release: LABORATORIOS SYVA, S.A.U. Avda. Párroco Pablo Díez, 49-57 24010 LEÓN - SPAIN 2. NAME OF THE VETERINARY MEDICINAL PRODUCT In France, Germany, Hungary, Italy, Poland, Spain and The Netherlands: LUTEOSYL 0.075 mg/ml solution for injection for cattle and pigs. d-cloprostenol In United Kingdom: PRELLIM 0.075 mg/ml solution for injection for cattle and pigs d-cloprostenol 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS d-cloprostenol (as d-cloprostenol sodium)... 0.075 mg/ml Chlorocresol... 1 mg/ml Luteosyl is a clear, colourless solution. 4. INDICATION(S) Cattle (cows) Indications for reproduction: synchronization or induction of oestrus. Induction of parturition. Therapeutic indication: ovarian dysfunction (persistent corpus luteum, luteal cyst), interruption of gestation including foetal mummification, endometritis/pyometra, delayed uterine involution. Pigs (sows) Indications for reproduction: Induction of parturition.

5. CONTRAINDICATIONS Do not use (during the whole or part of the pregnancy) unless it is desirable to induce parturition or therapeutic interruption of pregnancy. Do not use in case of hypersensitivity to the active substance, or to any of the excipients. Do not use in animal with spastic respiratory or gastro-intestinal diseases. 6. ADVERSE REACTIONS Occurrence of anaerobic infection is likely if anaerobic bacteria penetrate the tissue of the injection site. This applies especially to intramuscular injection and in particular to cows. Typical local reactions due to anaerobic infection are swelling and crepitus at the injection site. If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon. 7. TARGET SPECIES Cattle (cows) and Pigs (sows). 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION This veterinary medicinal product is only for intramuscular use : Cattle (cows): The recommended dose is 0.150 mg d-cloprostenol/animal, equivalent to 2 ml/animal. - Oestrus induction (also in cows with weak or silent heat): Administer the veterinary medicinal product after the presence of corpus luteum has been determined (6 th -8 th day of the cycle). Heat is normally observed after 48-60 hours. Inseminate 72-96 hours after the previous treatment. If heat is not observed, repeat after 11 days. - Parturition induction: Administer the veterinary medicinal product after the 270 th day of gestation. Parturition should occur 30-60 hours after treatment. - Oestrus synchronization: Administer the veterinary medicinal product twice (11 days apart). Inseminate artificially 72 and 96 hours after the second injection. - Ovarian dysfunction: After the presence of corpus luteum has been determined, administer the veterinary medicinal product and inseminate during the first heat after treatment. If no heat is observed, carry out another gynaecological examination and repeat the injection 11 days after the first treatment. Inseminate 72-96 hours after treatment. - Endometritis or pyometra: Administer 1 dose of veterinary medicinal product. Repeat treatment 10-11 days later if necessary.

- Gestation interruption: Administer the veterinary medicinal product during the first half of gestation. - Foetal mummification: Administer 1 dose of veterinary medicinal product. The foetus is expelled 3 or 4 days later. - Retarded uterine involution: Administer 1 dose of veterinary medicinal product and, if indicated, repeat treatment once or twice at 24 hour interval. Pigs (sows): The recommended dose is 0.075 mg d-cloprostenol/animal, equivalent to 1 ml/animal. - Parturition induction: Administer the veterinary medicinal product after day 112 of gestation. Repeat after 6 hours. Alternatively, 20 hours after the initial dose of d- cloprostenol, a myometrial stimulant (oxytocin or carazolol) may be administered. Following the protocol of double administration, in about 70% of cases, parturition occurs 20-30 hours after the first treatment. 9. ADVICE ON CORRECT ADMINISTRATION As with parenteral administration of any substance, basic antiseptic rules should be observed. The injection site must be thoroughly cleaned and disinfected in order to reduce the risk of infection with anaerobic bacteria. 10. WITHDRAWAL PERIOD Cows: Meat and offal: 1 day. Milk: 0 hours. Sows: Meat and offal: 1 day. 11. SPECIAL STORAGE PRECAUTIONS Keep out of the sight and reach of children. Protect from light. Keep the vial in the outer carton.avoid introduction of contamination. Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month Shelf life after first opening the container: 28 days. 12. SPECIAL WARNING(S) Special precautions for use in animals

To reduce the risk of anaerobic infections care should be taken to avoid injection through contaminated areas of skin. Clean and disinfect injection sites thoroughly before application. Pregnancy. Do not use in gestating animals unless it is desirable to induce parturition or therapeutic interruption of pregnancy. Pigs: use only when precise date of insemination is known. Administer on day 113 of gestation, at the earliest. The veterinary medicinal product administered earlier, may impair the viability and weight of piglets. Interaction with other medicinal products and other forms of interaction. Do not use in animals being treated with non-steroidal anti-inflammatories, as the synthesis of endogenous prostaglandins is inhibited. The activity of other oxytocic agents can be increased after the administration of Cloprostenol. Overdose (symptons, emergency procedures, antidotes): In safety studies, at 10 times the therapeutic dose, no adverse reactions are reported. As no specific antidote has been identified, in the case of overdose, symptomatic therapy is advisable. Incompabilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. Special precautions to be taken by the person administering the veterinary medicinal product to animals d-cloprostenol, like all F2 prostaglandins, can be absorbed through the skin and can produce bronchospasm and abortion. Women of child-bearing age, asthmatics and persons with bronchial problems or any other type of respiratory problem must avoid any contact or use disposable plastic gloves when administering the product. The veterinary medicinal product must be handled carefully to avoid ACCIDENTAL SELF-INJECTION OR SKIN CONTACT. Do not eat, drink or smoke while handling the product In case of accidental self injection seek medical advice and show the label to the physician. Seek medical advice immediately in case of any respiratory difficulty caused by accidental inhalation or inoculation.

In case of accidental skin contact, wash with soap and water immediately. 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY PRODUCTS OR WASTE MATERIALS IF ANY. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment. 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED September 2013 15. OTHER INFORMATION Package sizes: One glass vial of 2 ml in a cardboard box. One glass vial of 10 ml in a cardboard box. One glass vial of 20 ml in a cardboard box. Five glass vials of 20 ml in a cardboard box. Not all pack sizes may be marketed. For any information about this veterinary medicinal product, please contact the marketing authorisation holder. For animal treatment only - to be supplied only on veterinary prescription. When the vial is broached for the first time, using the in-use shelf-life which is specified on this package leaflet, the date on which any product remaining in the container should be discarded should be worked out. This discard date should be written in the space provided on the carton.